Teva Pharmaceutical Industries
10
18M
9
0.08
1
0.10
8
- Areas of investment
Summary
In 1901 was created Teva Pharmaceutical Industries, which is appeared as Corporate Investor. The venture was found in Asia in Israel. The leading representative office of defined Corporate Investor is situated in the Petah Tiqva.
The average startup value when the investment from Teva Pharmaceutical Industries is 50-100 millions dollars. Deals in the range of 10 - 50 millions dollars are the general things for fund. The top amount of exits for fund were in 2015. Considering the real fund results, this Corporate Investor is 13 percentage points more often commits exit comparing to other organizations. The top activity for fund was in 2006. Opposing the other organizations, this Teva Pharmaceutical Industries works on 49 percentage points more the average amount of lead investments. The fund is constantly included in less than 2 deals per year.
The current fund was established by Chaim Salomon, Moshe Levin, Yitschak Elstein.
The usual cause for the fund is to invest in rounds with 3-4 partakers. Despite the Teva Pharmaceutical Industries, startups are often financed by Biomedical Investments, Auriga Partners, Silicon Valley Bank. The meaningful sponsors for the fund in investment in the same round are Pitango Venture Capital, Israel Healthcare Ventures, Giza Venture Capital. In the next rounds fund is usually obtained by Novartis, Israel Healthcare Ventures, Clal Biotechnology Industries.
Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Ignyta, BiolineRx, Cocrystal Discovery. The fund has exact preference in a number of founders of portfolio startups. We can highlight the next thriving fund investment areas, such as Health Care, Therapeutics. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States.
Investments analytics
Analytics
- Total investments
- 10
- Lead investments
- 1
- Exits
- 8
- Rounds per year
- 0.08
- Follow on index
- 0.10
- Investments by industry
- Biotechnology (10)
- Therapeutics (7)
- Health Care (6)
- Medical Device (5)
- Pharmaceutical (2) Show 2 more
- Investments by region
-
- United States (5)
- Israel (4)
- United Kingdom (1)
- Peak activity year
- 2015
- Number of Unicorns
- 1
- Number of Decacorns
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 18
- Avg. valuation at time of investment
- 240M
- Group Appearance index
- 0.50
- Avg. company exit year
- 11
- Avg. multiplicator
- 3.63
- Strategy success index
- 0.43
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| TransPharma Medical | 24 Jul 2006 | Biotechnology, Health Care, Pharmaceutical | Late Stage Venture | 18M | North District, Israel, Israel |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.